Advertisement
Singapore markets close in 2 hours 56 minutes

  • Straits Times Index

    3,194.44
    +39.75 (+1.26%)
     

  • Nikkei

    38,140.12
    +178.32 (+0.47%)
     

  • Hang Seng

    16,429.06
    +177.22 (+1.09%)
     

  • FTSE 100

    7,847.99
    +27.63 (+0.35%)
     

  • Bitcoin USD

    61,279.82
    -2,643.10 (-4.13%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • Dow

    37,753.31
    -45.66 (-0.12%)
     

  • Nasdaq

    15,683.37
    -181.88 (-1.15%)
     

  • Gold

    2,391.50
    +3.10 (+0.13%)
     

  • Crude Oil

    82.80
    +0.11 (+0.13%)
     

  • 10-Yr Bond

    4.5850
    0.0000 (0.00%)
     

  • FTSE Bursa Malaysia

    1,544.32
    +3.90 (+0.25%)
     

  • Jakarta Composite Index

    7,149.97
    +19.13 (+0.27%)
     

  • PSE Index

    6,530.06
    +80.02 (+1.24%)
     

Ayala Pharmaceuticals (AYLA) Soars: Stock Adds 13.2% in Session

Zacks Equity Research
·2-min read

Ayala Pharmaceuticals, Inc. AYLA was a big mover last session, as the company saw its shares rise more than 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $11.00 to $12.94 in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Ayala Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the Medical - Drugs industry is Catalent, Inc. CTLT, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

ADVERTISEMENT

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Catalent, Inc. (CTLT) : Free Stock Analysis Report
 
Ayala Pharmaceuticals, Inc. (AYLA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research